PayerTalkCE Presents: Navigating the Evolving Treatment Landscape in Small Cell Lung Cancer: A Payer Perspective on Pathways, Sequencing, and Coverage

Learn About:

1. Managed care considerations for treatment selection, maintenance therapy, and formulary decision-making.
2. Current and emerging treatment strategies for ES-SCLC, including mechanisms of action and the rationale for sequencing therapies.
3. Evidence-based first-line and subsequent treatment options, with a focus on NCCN recommendations and key clinical trial data.
4. Safety, monitoring, and treatment duration considerations that impact coverage, utilization management, and reauthorization policies.
5. Access and operational factors, including site-of-care considerations and patient management throughout the treatment journey.

Expert Faculty Presenters

Ryan Haumschild, PharmD, MS, MBA Vice President of Pharmacy Emory Healthcare and Winship Cancer Institute Click here for biography Jacob Sands, MD Associate Chief of the Lowe Center for Thoracic Oncology Oncology Medical Director of the International Patient Center Dana-Farber Cancer Institute Assistant Professor Harvard Medical School Click here for biography

Target Audience
The primary target audience for this initiative comprises medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, and network physicians affiliated with various managed care organizations (MCOs), health systems, and other payer organizations.

Statement of Need/Program Overview
This webcast will provide managed care professionals with a practical, evidence-based review of the evolving treatment landscape in extensive-stage small cell lung cancer (ES-SCLC), with a focus on how emerging clinical data can inform coverage policies, oncology pathways, and utilization management strategies. Participants will explore the mechanisms of action, clinical evidence, and NCCN-recommended use of current first-line, maintenance, and subsequent therapy options; evaluate the impact of treatment sequencing and maintenance optimization on patient outcomes; and examine key considerations related to safety monitoring, response assessment, reauthorization criteria, and site-of-care decisions. Through real-world patient cases, attendees will gain insights into balancing clinical value, operational feasibility, and timely patient access in a rapidly changing ES-SCLC treatment environment.

Educational Objectives
At the conclusion of this activity, participants should be able to demonstrate improved ability to:

• Describe the mechanisms of action of current ES-SCLC therapies to understand the scientific rationale for combination and sequencing strategies
• Differentiate the NCCN-preferred first-line ES-SCLC by their categories of evidence, clinical trial data, and patient selection criteria to inform formulary and utilization management decisions
• Explain why maintenance therapy optimization is a critical managed care priority in ES-SCLC
• Compare the clinical evidence and NCCN categories of evidence for preferred subsequent therapy options to develop clinically aligned oncology pathway policies
• Assess the distinct safety profiles of SCLC therapies to inform coverage policies and monitoring mandates.
• Evaluate site-of-care implications for SCLC treatments to develop operationally appropriate access and delivery policies
• Outline NCCN-recommended response assessment schedules and treatment duration guidelines to inform utilization management and reauthorization criteria

Accreditation Information

Joint Accreditation Statement IIn support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: Coming Soon
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.